JP2005526696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526696A5 JP2005526696A5 JP2003528796A JP2003528796A JP2005526696A5 JP 2005526696 A5 JP2005526696 A5 JP 2005526696A5 JP 2003528796 A JP2003528796 A JP 2003528796A JP 2003528796 A JP2003528796 A JP 2003528796A JP 2005526696 A5 JP2005526696 A5 JP 2005526696A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- alkyl
- compound
- phenyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010036018 Pollakiuria Diseases 0.000 claims 1
- -1 R 1 Chemical group 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31888201P | 2001-09-14 | 2001-09-14 | |
| PCT/US2002/028912 WO2003024948A1 (en) | 2001-09-14 | 2002-09-10 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526696A JP2005526696A (ja) | 2005-09-08 |
| JP2005526696A5 true JP2005526696A5 (https=) | 2006-01-05 |
Family
ID=23239957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003528796A Withdrawn JP2005526696A (ja) | 2001-09-14 | 2002-09-10 | ベータ−３アドレナリン受容体アゴニストとして有用なベンゾフランおよびジヒドロベンゾフラン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6780859B2 (https=) |
| EP (1) | EP1430043A1 (https=) |
| JP (1) | JP2005526696A (https=) |
| CA (1) | CA2459454A1 (https=) |
| MX (1) | MXPA04001785A (https=) |
| WO (1) | WO2003024948A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706764A (en) | 1969-04-16 | 1972-12-19 | Yoshitomi Pharmaceutical | Phenethylaminomethyl-chromanones and- thiochromanones |
| US3803176A (en) | 1969-05-09 | 1974-04-09 | Novo Terapeutisk Labor As | Sulfonylurea derivatives |
| ZA844519B (en) | 1983-06-24 | 1985-02-27 | Hoffmann La Roche | Dihydrobenzopyran derivatives |
| US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
| DE3411992A1 (de) | 1984-03-31 | 1985-10-10 | Bayer Ag, 5090 Leverkusen | Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| FR2695387B1 (fr) | 1992-09-09 | 1994-10-21 | Adir | Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| US5541197A (en) | 1994-04-26 | 1996-07-30 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| US5516917A (en) | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
| JPH08165276A (ja) | 1994-12-14 | 1996-06-25 | Dainippon Pharmaceut Co Ltd | ２−アルキルアミノ−１−フェニルエタノール誘導体 |
| US5663194A (en) | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| FR2746395B1 (fr) | 1996-03-22 | 1998-04-17 | Adir | Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP3708624B2 (ja) | 1996-03-27 | 2005-10-19 | キッセイ薬品工業株式会社 | ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体 |
| EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| AU723895B2 (en) | 1997-01-29 | 2000-09-07 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| US6051586A (en) | 1997-12-19 | 2000-04-18 | Bayer Corporation | Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
-
2002
- 2002-09-10 US US10/241,250 patent/US6780859B2/en not_active Expired - Fee Related
- 2002-09-10 MX MXPA04001785A patent/MXPA04001785A/es unknown
- 2002-09-10 CA CA002459454A patent/CA2459454A1/en not_active Abandoned
- 2002-09-10 JP JP2003528796A patent/JP2005526696A/ja not_active Withdrawn
- 2002-09-10 EP EP02757693A patent/EP1430043A1/en not_active Withdrawn
- 2002-09-10 WO PCT/US2002/028912 patent/WO2003024948A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526696A5 (https=) | ||
| RU2328283C2 (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| JP5269758B2 (ja) | 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体 | |
| JP4854511B2 (ja) | 糖尿病治療剤 | |
| JP5149271B2 (ja) | 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体 | |
| TWI268925B (en) | 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them | |
| JP2010530431A5 (https=) | ||
| JP2009537559A5 (https=) | ||
| JP2008513498A5 (https=) | ||
| WO2012064559A1 (en) | Sgc stimulators | |
| RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| JP2016513719A (ja) | 重水素化２，４−チアゾリジンジオン及び治療方法 | |
| JP2007507494A5 (https=) | ||
| JP2019524747A (ja) | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 | |
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| JP2005519885A5 (https=) | ||
| RU2005110921A (ru) | N-замещенные 1н-индол-5-пропионовые кислоты в качестве предшественников агонистов, используемых для лечения диабета | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| WO2001072695A1 (en) | Neovascularization inhibitors | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| JP5765738B2 (ja) | ロスバスタチンおよびアトルバスタチン誘導体 | |
| ES2672777T3 (es) | Métodos de tratamiento de estados con mediación alfa-adrenérgica | |
| JPH03215426A (ja) | 血糖上昇抑制剤 | |
| JP2004526721A5 (https=) |